Sinomune to launch Almirall’s Seysara in China: Can it reshape acne treatment models?

Almirall’s Seysara gains NMPA approval for acne in China. Find out what this means for dermatology antibiotics, access, and Sinomune’s market role.

Almirall’s Seysara gains NMPA approval for acne in China. Find out what this means for dermatology antibiotics, access, and Sinomune’s market role.

Ascletis’ acne drug denifanstat advances with NDA acceptance in China. Explore how FASN targeting could disrupt acne care and redefine systemic treatments.